Trial Profile
MULTICENTER PHASE II STUDY OF IMC-A12 IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH CHEMOTHERAPY (NCI 8347).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 31 Oct 2016 Status changed from active, no longer recruiting to completed.
- 28 May 2015 Data from 74 patients across this and 3 other trials (see CT profiles 29397, 54727 and 219237) were presented at the 2015 American Society of Clinical Oncology annual meeting.
- 30 Mar 2012 Actual patient number 36 added as reported by ClinicalTrials.gov.